Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 2.30
LXRX's Cash-to-Debt is ranked lower than
69% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. LXRX: 2.30 )
Ranked among companies with meaningful Cash-to-Debt only.
LXRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.31  Med: 4.65 Max: No Debt
Current: 2.3
Equity-to-Asset 0.29
LXRX's Equity-to-Asset is ranked lower than
83% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. LXRX: 0.29 )
Ranked among companies with meaningful Equity-to-Asset only.
LXRX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.29  Med: 0.62 Max: 0.96
Current: 0.29
0.29
0.96
Altman Z-Score: -2.32
Beneish M-Score: 5.37
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -175.88
LXRX's Operating Margin % is ranked lower than
56% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. LXRX: -175.88 )
Ranked among companies with meaningful Operating Margin % only.
LXRX' s Operating Margin % Range Over the Past 10 Years
Min: -9955.46  Med: -639.94 Max: 1.13
Current: -175.88
-9955.46
1.13
Net Margin % -170.63
LXRX's Net Margin % is ranked lower than
57% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. LXRX: -170.63 )
Ranked among companies with meaningful Net Margin % only.
LXRX' s Net Margin % Range Over the Past 10 Years
Min: -10120.39  Med: -606.25 Max: -3.6
Current: -170.63
-10120.39
-3.6
ROE % -86.40
LXRX's ROE % is ranked lower than
69% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. LXRX: -86.40 )
Ranked among companies with meaningful ROE % only.
LXRX' s ROE % Range Over the Past 10 Years
Min: -86.4  Med: -43.42 Max: -1.64
Current: -86.4
-86.4
-1.64
ROA % -29.95
LXRX's ROA % is ranked higher than
51% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. LXRX: -29.95 )
Ranked among companies with meaningful ROA % only.
LXRX' s ROA % Range Over the Past 10 Years
Min: -32.59  Med: -27.19 Max: -0.83
Current: -29.95
-32.59
-0.83
ROC (Joel Greenblatt) % -723.19
LXRX's ROC (Joel Greenblatt) % is ranked lower than
58% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. LXRX: -723.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
LXRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -723.19  Med: -202.19 Max: 15.03
Current: -723.19
-723.19
15.03
3-Year Revenue Growth Rate 199.00
LXRX's 3-Year Revenue Growth Rate is ranked higher than
98% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. LXRX: 199.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
LXRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -71.6  Med: 13 Max: 328.1
Current: 199
-71.6
328.1
3-Year EBITDA Growth Rate -1.90
LXRX's 3-Year EBITDA Growth Rate is ranked lower than
54% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. LXRX: -1.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
LXRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -28.5  Med: -8.7 Max: 22.5
Current: -1.9
-28.5
22.5
3-Year EPS without NRI Growth Rate -1.40
LXRX's 3-Year EPS without NRI Growth Rate is ranked higher than
52% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. LXRX: -1.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
LXRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -68.6  Med: -11.1 Max: 29.1
Current: -1.4
-68.6
29.1
GuruFocus has detected 4 Warning Signs with Lexicon Pharmaceuticals Inc $LXRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LXRX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

LXRX Guru Trades in Q3 2016

Paul Tudor Jones 41,850 sh (+238.84%)
Mario Gabelli 14,600 sh (-9.32%)
Joel Greenblatt 47,635 sh (-83.86%)
» More
Q4 2016

LXRX Guru Trades in Q4 2016

Mario Gabelli 14,600 sh (unchged)
Paul Tudor Jones 30,574 sh (-26.94%)
Joel Greenblatt 27,102 sh (-43.10%)
» More
Q1 2017

LXRX Guru Trades in Q1 2017

Steven Cohen 382,500 sh (New)
Jim Simons 261,505 sh (New)
Mario Gabelli 14,600 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones 25,827 sh (-15.53%)
» More
Q2 2017

LXRX Guru Trades in Q2 2017

Jim Simons 384,097 sh (+46.88%)
Mario Gabelli 14,600 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:LXRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-03-31 Sold Out $13.68 - $16.73 $ 14.06-5%0
Joel Greenblatt 2016-12-31 Reduce -43.10%$13.83 - $19.3 $ 14.06-12%27,102
Joel Greenblatt 2016-09-30 Reduce -83.86%0.04%$13.88 - $19.24 $ 14.06-13%47,635
Mario Gabelli 2016-09-30 Reduce -9.32%$13.88 - $19.24 $ 14.06-13%14,600
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:ARRY, NYSE:EBS, NAS:MYOK, NAS:INVA, NAS:CORT, NAS:BPMC, NAS:XLRN, NYSE:CBM, NAS:HALO, NAS:RGEN, NAS:GBT, NYSE:BHVN, NAS:ACOR, NAS:ESPR, NAS:OMER, NAS:DVAX, NAS:AIMT, NAS:DERM, NAS:AKCA, NAS:AMRI » details
Traded in other countries:LX31.Germany,
Headquarter Location:USA
Lexicon Pharmaceuticals Inc operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease. The company mainly designs and develops drugs for therapeutic areas.

Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising drug targets. Lexicon then designs and develops drugs for these targets, which cover a broad spectrum of therapeutic areas. Following a restructuring in January 2014, Lexicon is focusing efforts on two drugs: sotagliflozin (LX4211) in diabetes, which is partnered with Sanofi, and Xermelo (telotristat etiprate) in carcinoid syndrome, which is partnered with Ipsen outside the U.S.

Top Ranked Articles about Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study Of Sotagliflozin
Lexicon Pharmaceuticals To Present At 2017 Wedbush PacGrow Healthcare Conference
Lexicon Pharmaceuticals Announces Opt-In Decision For U.S. Co-Promotion Of Sotagliflozin With Sanofi In Type 1 Diabetes
Lexicon Pharmaceuticals To Host Second Quarter 2017 Financial Results Conference Call And Webcast On August 1, 2017
Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo® (Telotristat Ethyl)
NCCN Guidelines For Neuroendocrine Tumors Include XERMELO In Combination With Somatostatin Analog Therapy As A Recommended Treatment Option For Patients With Carcinoid Syndrome Diarrhea
Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes
Lexicon Pharmaceuticals To Present New Clinical Data At 77th American Diabetes Association Scientific Sessions
Lexicon Pharmaceuticals To Present At Upcoming Investor Conferences
Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal InTandem1 Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes

Ratios

vs
industry
vs
history
PB Ratio 13.96
LXRX's PB Ratio is ranked lower than
87% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. LXRX: 13.96 )
Ranked among companies with meaningful PB Ratio only.
LXRX' s PB Ratio Range Over the Past 10 Years
Min: 0.66  Med: 3.32 Max: 17.76
Current: 13.96
0.66
17.76
PS Ratio 18.08
LXRX's PS Ratio is ranked lower than
61% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. LXRX: 18.08 )
Ranked among companies with meaningful PS Ratio only.
LXRX' s PS Ratio Range Over the Past 10 Years
Min: 2.63  Med: 25 Max: 1440
Current: 18.08
2.63
1440
EV-to-EBIT -9.64
LXRX's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. LXRX: -9.64 )
Ranked among companies with meaningful EV-to-EBIT only.
LXRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -229  Med: -3.9 Max: 484.7
Current: -9.64
-229
484.7
EV-to-EBITDA -9.82
LXRX's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. LXRX: -9.82 )
Ranked among companies with meaningful EV-to-EBITDA only.
LXRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -281.1  Med: -4.1 Max: 357.4
Current: -9.82
-281.1
357.4
Current Ratio 1.86
LXRX's Current Ratio is ranked lower than
75% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. LXRX: 1.86 )
Ranked among companies with meaningful Current Ratio only.
LXRX' s Current Ratio Range Over the Past 10 Years
Min: 0.95  Med: 6.28 Max: 31.11
Current: 1.86
0.95
31.11
Quick Ratio 1.85
LXRX's Quick Ratio is ranked lower than
70% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. LXRX: 1.85 )
Ranked among companies with meaningful Quick Ratio only.
LXRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 6.28 Max: 31.11
Current: 1.85
0.95
31.11
Days Inventory 100.30
LXRX's Days Inventory is ranked higher than
71% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. LXRX: 100.30 )
Ranked among companies with meaningful Days Inventory only.
LXRX' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 100.3
Current: 100.3
0
100.3
Days Sales Outstanding 22.57
LXRX's Days Sales Outstanding is ranked higher than
74% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. LXRX: 22.57 )
Ranked among companies with meaningful Days Sales Outstanding only.
LXRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.56  Med: 30.31 Max: 461.86
Current: 22.57
2.56
461.86
Days Payable 21.00
LXRX's Days Payable is ranked higher than
58% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. LXRX: 21.00 )
Ranked among companies with meaningful Days Payable only.
LXRX' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 21
Current: 21
0
21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.40
LXRX's 3-Year Average Share Buyback Ratio is ranked lower than
52% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. LXRX: -12.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LXRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -52  Med: -15 Max: -6.9
Current: -12.4
-52
-6.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 156.22
LXRX's Price-to-Tangible-Book is ranked lower than
97% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. LXRX: 156.22 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
LXRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.89  Med: 4.4 Max: 194.94
Current: 156.22
0.89
194.94
Price-to-Median-PS-Value 0.72
LXRX's Price-to-Median-PS-Value is ranked higher than
66% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. LXRX: 0.72 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LXRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 0.61 Max: 47.6
Current: 0.72
0.11
47.6
Earnings Yield (Greenblatt) % -10.38
LXRX's Earnings Yield (Greenblatt) % is ranked lower than
53% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. LXRX: -10.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LXRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1305.1  Med: -15.5 Max: 52.6
Current: -10.38
-1305.1
52.6

More Statistics

Revenue (TTM) (Mil) $81.10
EPS (TTM) $ -1.32
Beta0.07
Short Percentage of Float59.15%
52-Week Range $13.41 - 19.62
Shares Outstanding (Mil)105.58

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 84 123 215
EPS ($) -1.46 -1.10 0.31
EPS without NRI ($) -1.46 -1.10 0.31
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:LXRX

Headlines

Articles On GuruFocus.com
Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study Of Sot Aug 15 2017 
Lexicon Pharmaceuticals To Present At 2017 Wedbush PacGrow Healthcare Conference Aug 03 2017 
Lexicon Pharmaceuticals Announces Opt-In Decision For U.S. Co-Promotion Of Sotagliflozin With Sanofi Jul 31 2017 
Lexicon Pharmaceuticals To Host Second Quarter 2017 Financial Results Conference Call And Webcast On Jul 24 2017 
Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo® (Telotristat Ethyl) Jul 21 2017 
NCCN Guidelines For Neuroendocrine Tumors Include XERMELO In Combination With Somatostatin Analog Th Jun 19 2017 
Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotaglifloz Jun 09 2017 
Lexicon Pharmaceuticals To Present New Clinical Data At 77th American Diabetes Association Scientifi Jun 05 2017 
Lexicon Pharmaceuticals To Present At Upcoming Investor Conferences May 31 2017 
Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal InTandem1 Phase 3 Study For So May 11 2017 

More From Other Websites
See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc. Aug 17 2017
Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study Of... Aug 15 2017
Edited Transcript of LXRX earnings conference call or presentation 1-Aug-17 12:00pm GMT Aug 12 2017
Lexicon Pharmaceuticals To Present At 2017 Wedbush PacGrow Healthcare Conference Aug 03 2017
Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US :... Aug 02 2017
Lexicon reports 2Q loss Aug 01 2017
Lexicon Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LXRX) : August 1, 2017 Aug 01 2017
Lexicon Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides A Business Update Aug 01 2017
Lexicon Pharmaceuticals Announces Opt-In Decision For U.S. Co-Promotion Of Sotagliflozin With Sanofi... Jul 31 2017
3 Stocks That Could Be Life-Changers Jul 25 2017
Lexicon Pharmaceuticals To Host Second Quarter 2017 Financial Results Conference Call And Webcast On... Jul 24 2017
Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo® (Telotristat Ethyl) Jul 21 2017
Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US :... Jul 19 2017
NCCN Guidelines For Neuroendocrine Tumors Include XERMELO In Combination With Somatostatin Analog... Jun 19 2017
3 Top Healthcare Stocks You Haven't Thought Of Jun 18 2017
3 Top-Performing Biotech Stocks This Week Jun 16 2017
Edited Transcript of LXRX earnings conference call or presentation 2-May-17 10:00pm GMT Jun 13 2017
Company News for June 12, 2017 Jun 12 2017
Corporate News Blog - Lexicon Pharma's Diabetes Drug Sotagliflozin Shows Positive Top-line Results... Jun 12 2017
Today's Research Reports on Stocks to Watch: Lexicon Pharmaceuticals and Adamis Pharmaceuticals Jun 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}